Currently, the only medicine approved by the FDA and European Medicines Agency (EMA) that uses nanostructures to deliver RNA is Onpattro® (mentioned in section “Small Interfering RNAs (siRNAs)”); Onpattro® is a lipid nanoparticle-based drug product that transports patisiran, an siRNA molecule for the treatment of TTR amyloidosis (Rizk and Tuzmen, 2019). This evidence concerns the gene TTR and amyloidosis.